About UsInd Swift group, as pharmaceutical business model is one of India's largest manufacturer of high growth multi segment pharmaceutical finished dosage forms and API's (Active Pharmaceutical Ingredients). Manufacturing of Pharmaceutical finished dosage are carried out at 7 state-of-the art manufacturing facilities which are second to the none are duly certified and approved by WHO GMP, spread over an area of 12, 00, 000 sq. ft. with manufacturing capacities confirming to stringent TGA/MHRA approvals; possessing an installed capacities of 3 billion units comprising tablets, capsules, Ointments, Injectable, Liquids & Dry Syrup (all latest formulations with a marketing network. Our API section has spread over an area of 7 Lac sq. ft, carried out at 3 different state-of-th-art units approved by USFDA and E.U regulatory authorities with a marketing network spread over in 40 countries viz. Europe/USA/Middle East possessing 2 patented molecules with 11 molecules in offing It possesses 50% exports percentage. Ind Swift entered into bulk drugs with its own Research and Development facility and laboratories at Derabassi. Later on, those units got USFDA approval and got the process patents for Clarithromycin for US and allied markets and further five more patent drugs await clearance for the moment. A joint venture with Iran has also been signed for the manufacturing of Clarithormycin with construction underway and will start operations by the end 2008. The company has offices and supplies pharma drugs not only in India but overseas as well. | 
Processing...
